Trial Profile
A study to evaluate the risk of infectious complications in patients with chronic lymphocytic leukaemia treated with Ibrutinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 21 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association